651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA

Key Points

• Kepler Cheuvreux Suisse SA initiated a new position in Pfizer, buying 651,996 shares in Q3 valued at about $16.6 million, joining other institutions that have recently increased their stakes (institutional ownership ~68%).
• Pfizer posted a positive Phase‑2 readout for tilrekimig (PF‑07275315) and plans late‑stage testing, strengthening its dermatology pipeline; however, a 126.47% payout ratio (annualized yield ~6.3%) has raised investor concern about potential dividend pressure.

Kepler Cheuvreux Suisse SA bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 651,996 shares of the biopharmaceutical company's stock, valued at approximately $16,613,000.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the period. United Bank grew its position in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. ProShare Advisors LLC grew its position in Pfizer by 10.6% in the 2nd quarter. ProShare Advisors LLC now owns 1,094,571 shares of the biopharmaceutical company's stock worth $26,532,000 after purchasing an additional 104,687 shares during the last quarter. Finally, Fidelis Capital Partners LLC increased its stake in shares of Pfizer by 73.2% in the second quarter. Fidelis Capital Partners LLC now owns 27,283 shares of the biopharmaceutical company's stock valued at $653,000 after purchasing an additional 11,533 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase‑2 readout for tilrekimig (PF‑07275315) — the study met its primary endpoint (EASI‑75 at Week 16) and Pfizer plans late‑stage testing, which materially strengthens the company’s dermatology pipeline and future growth prospects. Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis Pfizer's eczema drug meets main goal in mid-stage trial
• Neutral Sentiment: FDA approved leucovorin for a rare genetic condition but not for autism — important regulatory news for the sector but not directly tied to Pfizer’s marketed products or near‑term revenue. FDA Approves Leucovorin—But Not For Autism
• Neutral Sentiment: Patent activity around tafamidis (a competing transthyretin amyloidosis drug) and related market moves lifted other small caps — the BridgeBio story signals shifting patent dynamics that could influence competitive positioning over time but the impact on Pfizer is uncertain. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up
• Neutral Sentiment: BioNTech cofounders stepping down rattled biotech sentiment broadly; this is sector noise that can increase volatility but does not directly affect Pfizer’s fundamentals. BioNTech Cofounders To Step Down. Stock Crumbles.
• Negative Sentiment: Investor concern over Pfizer’s payout ratio (reported >100%) and a quarterly loss raised the specter of dividend pressure — this remains a key negative risk that can cap upside and prompt selling. Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
• Negative Sentiment: Despite the positive eczema data, some reports noted shares dipped earlier — signaling profit‑taking and investor skepticism that new pipeline data will immediately translate to material revenue. That caution can mute sustained rallies. Pfizer shares dip despite positive trial results for skin condition drug

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Morgan Stanley reduced their price objective on Pfizer from $32.00 to $28.00 and set an "equal weight" rating for the company in a research report on Friday, December 12th. UBS Group initiated coverage on Pfizer in a research report on Tuesday, January 6th. They issued a "neutral" rating and a $25.00 target price on the stock. Argus raised Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price on the stock in a research note on Monday, March 2nd. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, BMO Capital Markets reissued an "outperform" rating and set a $30.00 price target on shares of Pfizer in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $28.05.

Pfizer Trading Up 1.2%

Pfizer stock opened at $27.12 on Wednesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market capitalization of $154.22 billion, a PE ratio of 19.94 and a beta of 0.47. The firm has a 50 day simple moving average of $26.38 and a 200-day simple moving average of $25.49.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Friday, January 23rd were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend was Friday, January 23rd. Pfizer's payout ratio is currently 126.47%.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.